ROI Widget

Patients are only 50 to 65 percent adherent with their medication, and poor adherence reduces a clinical trial’s ability to detect a treatment effect if one exists. The highest and best use of IMC’s intelligent packaging solutions is early detection of non-adherence and correction through self-discovery, education and motivational counselling.

Modeling the interrelationship between statistical power, sample size and medication adherence shows that for every percent adherence is increased, a trial's sample size can be reduced by two percent while holding statistical power constant. With 35 to 50 percent non-adherence there’s lots of room for improvement – and ROI.

Trial Size (N) from Pre-Trial Power Calculations		Patients
Number of Med-ic Packages per Patient		Packages
Estimated Cost to Process one Patient Estimated Per-Patient Clinical Trial Costs by Phase, 2013 Phase I $38,500. Phase II $40,000. Phase III $42,000. Phase IV $16,500. PhRMA/Battelle. Biopharmaceutical Industry-Sponsored Clinical Trials: Impact on State Economies, March 2015.		USD
Estimated Time to Enrol N Patients First patient, first visit to last patient, first visit.		Weeks
Estimated Percentage Adherence Increase Due to Med-ic Conservatively estimated improvement in adherence will vary from 5 to 15 percent according to the patient population and the study format.		Percent
Estimated revenue per additional week on patent		x million USD

Med-ic reduced N (from )	Patients
Direct savings from reduced N Direct savings are due to the reduced cost of processing the smaller sample size required when monitoring and coaching adherence.	USD
Additional weeks of patent protection	Weeks
TOTAL ROI	USD

Request the full Background Report

ROI Widget

NFC Forum Certified

Our Solutions

Our Products

Did you know?